For research use only. Not for therapeutic Use.
LG 100268（Cat No.:R007997）is a selective retinoid X receptor (RXR) agonist, specifically designed to modulate RXR signaling pathways without activating retinoic acid receptors (RARs). By selectively binding to RXRs, LG 100268 influences gene expression linked to cell differentiation, lipid metabolism, and immune responses. This compound is valuable in research for treating metabolic disorders, certain cancers, and inflammatory diseases, as it helps control cellular processes involved in disease progression. Its receptor specificity makes LG 100268 an important tool for studying RXR-related mechanisms and developing targeted therapies with fewer side effects.
| Catalog Number | R007997 |
| CAS Number | 153559-76-3 |
| Synonyms | 6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]-3-Pyridinecarboxylic Acid; AGN 192620; ALRT 268; CD 3127; LG 268; LGD 100268; LGD 1268; |
| Molecular Formula | C24H29NO2 |
| Purity | ≥95% |
| Target | RXR agonist |
| Storage | -20°C |
| IUPAC Name | 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid |
| InChI | InChI=1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27) |
| InChIKey | SLXTWXQUEZSSTJ-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(C=C1C3(CC3)C4=NC=C(C=C4)C(=O)O)C(CCC2(C)C)(C)C |
| Reference | 1:Clin Cancer Res. 2002 Oct;8(10):3270-5. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.Suh N,Lamph WW,Glasebrook AL,Grese TA,Palkowitz AD,Williams CR,Risingsong R,Farris MR,Heyman RA,Sporn MB, PMID: 12374698 </br><span>Abstract:</span> The selective estrogen receptor modulator arzoxifene and the rexinoid LG 100268 were active not only as single agents for prevention and treatment of breast cancer in the rat model that uses nitrosomethylurea as the carcinogen but also showed striking synergy, both preventively and therapeutically, in a series of six experiments with a total of 465 rats. Mechanistic studies in cell culture reported here suggest that enhancement of stromal-epithelial interactions may contribute to this synergy. The possible clinical use of the combination of arzoxifene and LG 100268 for prevention of breast cancer in women at high risk, for treatment of women in the adjuvant setting, or for treatment of end-stage disease should now be considered. |
